← Investor PortalInterested in the Company? Request more Information

MD200982

This neurotechnology company presents a compelling investment opportunity as it transforms chronic pain and neurological disorder treatment. Using AI-driven, non-invasive neurofeedback, their flagship device provides an effective, drug-free alternative to traditional treatments, tackling a market valued at $1.8 trillion globally.

With regulatory clearance, proven clinical efficacy, and substantial early traction, they are on track for rapid expansion. Raising $10 million, the company aims to scale production, extend applications to anxiety and ADHD, and accelerate R&D, making this a promising entry point into the high-growth neurotechnology sector.

Overview

Industry: Medical Devices, Healthcare Technology, Neurotechnology
Founded: 2015
Mission: To transform chronic pain and neurological disorder treatment by offering drug-free, AI-powered neurofeedback solutions that are accessible, safe, and tailored to individual needs.

Problem & Solution

Problem: Chronic pain management is heavily reliant on opioids and other medications, often leading to addiction, high healthcare costs, and variable efficacy in treating pain at the neurological level.
Solution: The company’s flagship device utilizes EEG technology in a non-invasive headset to analyze and adjust brain activity through neurofeedback. This drug-free solution works to “retrain” the brain, providing lasting pain relief without the risks associated with pharmaceuticals.

Market Potential

Target Market: Chronic pain and mental health treatment markets, expanding to broader neurological applications.
Total Addressable Market (TAM): Chronic pain and neurological treatment market is valued at $1.8 trillion worldwide, covering more than 1.5 billion affected individuals.
Serviceable Obtainable Market (SOM): With plans to capture 2 million patients in the U.S. and EU, the company projects potential revenues of approximately $1.2 billion within the next five to seven years.
Growth Rate: Chronic pain treatment is expected to grow at a 6.9% CAGR due to demand for drug-free alternatives and rising awareness about mental health.

Product

Flagship Device: The wearable headset uses EEG to track brainwave data in real-time, delivering personalized neurofeedback to alter brain response to pain.
Technology: Brain-Computer Interface (BCI) paired with Electroencephalography (EEG) captures brain data and translates it into therapeutic neurofeedback.
Development Stage: Fully developed and market-ready, with regulatory clearance across the U.S., UK, and New Zealand.
Future Applications: In addition to chronic pain, the company is expanding its neurofeedback technology to address anxiety, ADHD, depression, and other neurological conditions.

Business Model

Revenue Streams:
‍
→ Device Sales: One-time purchase for consumers and healthcare providers.
→ Subscription: Annual software subscription supporting continuous therapy and data analytics
Sales Channels: Direct-to-consumer, partnerships with healthcare providers, and potential B2B sales through healthcare networks.
Customer Retention Strategy: Built on a “patient-for-life” model, the company maintains high retention by addressing chronic conditions and ensuring continual app and software updates.

Financials

Funding Requirements: $10 million to scale production, enhance R&D for new applications, and fund further clinical trials.
Revenue: Early revenue projections in the multi-million dollar range, with potential for exponential growth as market adoption increases.
Burn Rate: Estimated at $250,000/month, providing runway for 12 months with current resources.
Financial Metrics:

→ Customer Acquisition Cost (CAC): $60 per customer
→ Lifetime Value (LTV): Estimated at $2,880 over five years, with the likelihood of longer retention.
→ Gross Margin: 75% due to minimal variable costs.
→ Net Profit Margin: 30% projected once economies of scale are reached.

Competitive Landscape

Direct Competitors: Traditional opioid treatments, physical therapy, and clinical neurofeedback devices that require in-office visits.
Indirect Competitors: Pharmaceutical solutions and therapy-based treatments for chronic pain.
Competitive Advantage:

→ The company’s device is home-based, removing the need for costly in-clinic visits.
→ High accessibility and affordability compared to existing neurofeedback therapies.
→ A scalable, FDA-cleared alternative to traditional therapies with data-driven insights for both users and healthcare providers.

Traction & Milestones

User Adoption: Over 25,000 treatments delivered to date, with an anticipated user base of 1 million within the next five years.
Partnerships: Collaborations with health organizations for clinical validation and distribution networks.
Recognition: Recently recognized by key industry organizations for innovation in the healthcare and mental health sectors.

Funding Allocation

Manufacturing and Production: $4 million to meet increased demand and scalability.
Sales and Marketing: $1.7 million to expand market presence and drive adoption.
Research and Clinical Validation: $1.2 million for new product trials and extended applications.
General Administrative and IP: Ensuring regulatory compliance and intellectual property protection.

Exit Strategy

Acquisition Targets: Large healthcare or neurotechnology companies seeking innovation in non-invasive treatment options.
Timeline: Targeting a three- to five-year exit window, with acquisition or IPO as potential options depending on growth and market response.

Pitch Deck

View the deck through the link below—while some unique identifiers have been removed, it still offers a great overview. For access to detailed investor materials, please reach out to us, as full decks are only shared upon request to maintain confidentiality and exclusivity.

View Pitch Deck